Interventional Recruiting
NCT06512311 on ClinicalTrials.gov
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening
Official title: Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial (ATTRACT)
- Sponsor: Medical University of Vienna
- Enrollment: 240 (Estimated)
- Study start: 2024-07-10 (Actual)
- Primary completion: 2030-12-31 (Estimated)
- Study completion: 2031-12-31 (Estimated)
- Allocation: Randomized
- InterventionModel: Parallel
- Masking: None
- PrimaryPurpose: Other
Brief Summary
Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach.
Conditions
- Glioblastoma
Intervention / Treatment
- Diagnostic Test: CBMed Drug Screening Plattform
Primary Outcome Measures
-
Overall survival time
(From date of randomization until date of death from any cause or last follow up whichever came first, assessed up to 144 months)
Change in overall survival in patients receiving extensive diagnostic work up including the standard histology analysis and PDC- based drug screening in addition (interventional arm) compared to patients receiving only standard histology diagnostic work up (standard arm)
Countries
Austria
Locations and Investigators
-
AKH Vienna, Department for Internal Medicine I, Oncology, Vienna, Austria (Recruiting)
- Anna Berghoff, MD
- Marika Rosner